•  
  •  
  •  
  •  

2026-08-11 20:30:32

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Lemon Tree Hotels signs Second hotel in Mcleodganj
  • Axis Mutual Fund launches Axis Nifty Energy Index Fund & Axis Nifty Energy ETF NFOs offering exposure to India's evolving capital energy ecosystem
  • Websol Energy Q1FY27 Revenue up 70% YoY at Rs 373 crore; Company Prepays Entire IREDA Term Loan
  • CPPIB to Invest ₹3,000 Crore in Prestige Estates' Hospitality Arm PHVL for Up to 28% Stake
  • Krystal Integrated Services Consortium Secures ₹740 Crore Urban Wastewater Contracts in Maharashtra

Keywords Selected:  NatcoPharma

Research

  • Natco Pharma - Natco and Teva launch Revlimid in the US - ICICI Securities

Stock Report

  • Alembic Pharmaceuticals Limited's Partner NATCO Pharma Limited receives USFDA Tentative Approval for Olaparib Tablets, 100 mg and 150 mg
  • NATCO receives Tentative Approval for Olaparib Tablets from the U.S. FDA
  • NATCO Pharma Ltd completes acquisition of additional 13.25% stake in Adcock Ingram Holdings Proprietary Ltd
  • NATCO Pharma Ltd gets approval from its Board of Directors for increasing its stake in Adcock Ingram Holdings Proprietary Ltd to 49%
  • NATCO and Lupin receive approval from U.S. FDA for Eribulin Mesylate Injection
  • NATCO Pharma Launches Semaglutide Generic Injection Multi Dose Vials in India at the Most Affordable Price Starting from MRP INR 1,290
  • NATCO announces launch of Pomalidomide Capsules (generic of Pomalyst&®) in the U.S. market
  • Eris Lifesciences Ltd announces Strategic Partnership with Natco Pharma Ltd for Semaglutide Launch in India
  • NATCO receives Tentative Approval for Erdafitinib Tablets from USFDA
  • NATCO Pharma Ltd receives 7 Observations from USFDA for API unit at Manali, Chennai
  • Adcock ingram completes delisting from JSE; NATCO Pharma acquires 35.75% stake
  • NATCO announces launch of its Everolimus tablets, 1 mg, (generic of Zortress®)
  • NATCO Pharma Limited - Legal update regarding Risdiplam
  • Legal update regarding Risdiplam - Commercial Appellate Division of the Hon'ble Delhi High Court Dismissed Appeal
  • NATCO Pharma Ltd updates on acquisition of Adcock Ingram
  • NATCO launches Bosentan Tablets for Oral Suspension in the United States with 180-day exclusivity
  • NATCO Pharma Ltd announces conclusion of USFDA inspection at Pharma Division, Kothur
  • USFDA inspection at the API manufacturing plant located in Mekaguda, Hyderabad
  • NATCO Pharma Ltd - Legal Update regarding Risdiplam
  • Mylan and Novo Nordisk reach settlement of US patent ligitation related to Ozempic
  • NATCO Pharma Canada Inc. announces US$ 8 million investment in eGenesis, Inc.
  • Natco Pharma Ltd announces submission of Abbreviated New Drug Application
  • NATCO Pharma Ltd updates on complaint by Fresenius
  • NATCO Pharma Ltd receives warning letter from USFDA for facility in Kothur, Telangana

Latest Post

  • Lemon Tree Hotels signs Second hotel in Mcleodganj
  • Axis Mutual Fund launches Axis Nifty Energy Index Fund & Axis Nifty Energy ETF NFOs offering exposure to India's evolving capital energy ecosystem
  • Websol Energy Q1FY27 Revenue up 70% YoY at Rs 373 crore; Company Prepays Entire IREDA Term Loan
  • CPPIB to Invest ₹3,000 Crore in Prestige Estates' Hospitality Arm PHVL for Up to 28% Stake
  • Krystal Integrated Services Consortium Secures ₹740 Crore Urban Wastewater Contracts in Maharashtra


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025